Pretomanid: The latest USFDA-approved anti-tuberculosis drug

Article Properties
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis European Journal of Clinical Microbiology & Infectious Diseases
  • Medicine: Internal medicine: Infectious and parasitic diseases
  • Science: Microbiology
 36 2019
A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis Expert Opinion on Drug Safety
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 22 2019
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis Antimicrobial Agents and Chemotherapy
  • Science: Microbiology
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2015
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin Antimicrobial Agents and Chemotherapy
  • Science: Microbiology
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2014
Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824 Antimicrobial Agents and Chemotherapy
  • Science: Microbiology
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2011
Citations
Title Journal Journal Categories Citations Publication Date
Third Generation Solid Dispersion-Based Formulation of Novel Anti-Tubercular Agent Exhibited Improvement in Solubility, Dissolution and Biological Activity The AAPS Journal
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 2024
Pretomanid development and its clinical roles in treating tuberculosis Journal of Global Antimicrobial Resistance
  • Science: Microbiology
  • Medicine: Internal medicine: Infectious and parasitic diseases
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
 7 2022
Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis

 Microorganisms
  • Science: Biology (General)
  • Science: Microbiology
 2 2022
WITHDRAWN: Pretomanid for the treatment of Mycobacterium tuberculosis: Evidence on the development and clinical roles Journal of Infection and Public Health
  • Medicine: Internal medicine: Infectious and parasitic diseases
  • Medicine: Public aspects of medicine
  • Medicine: Internal medicine: Special situations and conditions: Industrial medicine. Industrial hygiene
  • Medicine: Internal medicine: Infectious and parasitic diseases
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
 2021
Screening and Identification of a Novel Anti-tuberculosis Compound That Targets Deoxyuridine 5′-Triphosphate Nucleotidohydrolase

 Frontiers in Microbiology
  • Science: Microbiology
  • Science: Microbiology
 2 2021
Citations Analysis
Category Category Repetition
Science: Microbiology3
Medicine: Therapeutics. Pharmacology3
Science: Biology (General)2
Medicine: Internal medicine: Infectious and parasitic diseases2
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy2
Medicine: Public aspects of medicine: Toxicology. Poisons2
Science: Chemistry: Organic chemistry1
Science: Chemistry: General. Including alchemy1
Science: Chemistry1
Medicine: Public aspects of medicine1
Medicine: Internal medicine: Special situations and conditions: Industrial medicine. Industrial hygiene1
Medicine: Pharmacy and materia medica1
The category Science: Microbiology 3 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled WITHDRAWN: Pretomanid for the treatment of Mycobacterium tuberculosis: Evidence on the development and clinical roles and was published in 2021. The most recent citation comes from a 2024 study titled Third Generation Solid Dispersion-Based Formulation of Novel Anti-Tubercular Agent Exhibited Improvement in Solubility, Dissolution and Biological Activity. This article reached its peak citation in 2021, with 4 citations. It has been cited in 7 different journals, 85% of which are open access. Among related journals, the The AAPS Journal cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year